Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 8/20 | 0.57 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | TEC | P42680 | 1/20 | 0.41 |
| ▸ | TXK | P42681 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125362 | 0.89 | AKT1 (0.59) | AKT1NEK1AKT3ROCK1CCNK | |
| SCHEMBL14493840 | 0.88 | NEK1 (0.64) | AKT1NEK1CITAKT3ROCK1 | |
| SCHEMBL4592540 | 0.88 | AKT1 (0.67) | AKT1NEK1AKT3ROCK1AKT2 | |
| SCHEMBL12346430 | 0.86 | AKT1 (0.61) | AKT1NEK1CITAKT3ROCK2 | |
| SCHEMBL12346484 | 0.84 | AKT1 (0.56) | AKT1NEK1AKT3AKT2TEC | |
| SCHEMBL10124948 | 0.83 | AKT1 (0.53) | AKT1NEK1CITAKT3ROCK2 | |
| SCHEMBL10124969 | 0.83 | AKT1 (0.62) | AKT1NEK1CITROCK1TEC | |
| SCHEMBL14494287 | 0.81 | AKT1 (0.58) | AKT1NEK1CITAKT3AKT2 | |
| SCHEMBL14493838 | 0.80 | AKT1 (0.66) | AKT1CITIKBKBCHUK | |
| SCHEMBL4791074 | 0.80 | AKT1 (0.58) | AKT1NEK1CITROCK1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | AKT1 109/4885NEK1 668/4885CIT 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.